Product Details

Uniprot No.

Target Names

UBD

Alternative Names

Diubiquitin antibody; FAT10 antibody; GABBR1 antibody; UBD 3 antibody; Ubd antibody; UBD_HUMAN antibody; Ubiquitin D antibody; Ubiquitin like protein FAT10 antibody; Ubiquitin-like protein FAT10 antibody

Species Reactivity

Human

Immunogen

A synthesized peptide from human UBD protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

4B6

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, FC

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Protocols

ELISA Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Ubiquitin D, also known as FAT10, represents a fascinating member of the ubiquitin-like modifier family with distinct roles in protein degradation and immune regulation. Unlike conventional ubiquitin, FAT10 targets proteins directly for proteasomal destruction without requiring deubiquitination, making it a key player in inflammatory responses and cellular stress pathways. Its expression is strongly induced by interferon-gamma and TNF-alpha, positioning it as an important marker in studies of immune activation, infection biology, and cancer research where aberrant FAT10 expression has been increasingly documented.

This recombinant monoclonal antibody, clone 4B6, offers researchers the reproducibility essential for longitudinal studies and multi-site collaborations. Developed using recombinant technology with a defined sequence, this rabbit IgG eliminates the lot-to-lot variability that can compromise experimental consistency. The antibody was raised against a synthetic peptide derived from human UBD protein and subsequently purified by affinity chromatography to ensure high specificity.

Validation through flow cytometry demonstrates reliable intracellular detection of UBD in human 786-O renal carcinoma cells. The overlay histogram analysis shows clear separation between antibody-stained and isotype control populations, confirming specific signal detection under optimized fixation and permeabilization conditions. Recommended working dilutions for flow cytometry range from 1:50 to 1:200, providing flexibility to optimize signal intensity based on expression levels in your experimental system.

For researchers investigating ubiquitin-like modification pathways, inflammatory signaling, or the intersection of immune responses with protein homeostasis, this antibody provides a dependable tool validated for human samples in flow cytometric applications.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN).

Gene References into Functions

the intrinsic instability of FAT10 together with its disordered N-terminus enables the rapid, joint degradation of FAT10 and its substrates. PMID: 30127417
Overexpression of FAT10 promotes cisplatinresistant bladder cancer formation. These results indicated FAT10 may be a novel target for the treatment of bladder cancer. PMID: 29749526
the results of the present study suggest that FAT10 may be involved in DDR and therefore the progression of tumorigenesis. PMID: 29620277
Up-Regulation of UBD Transcript is associated with focal segmental glomerulosclerosis. PMID: 29531077
FAT10 promotes tumor proliferation by directly stabilizing Survivin protein in breast cancer cells. PMID: 27806337
our data suggest that FAT10 was upregulated via retinoic acid-induced protein I and NF-kappaB during H5N1 avian influenza virus infection. And the upregulated FAT10 promoted H5N1 viral replication by inhibiting type I IFN. PMID: 27354218
we show how FAT10 stabilizes the translation elongation factor eEF1A1, which contributes to cancer cell proliferation PMID: 27312528
this study revealed a novel function of LMO2 involving in the regulatory hierarchy of UBA6-USE1-FAT10ylation pathway by targeting the E1 enzyme UBA6. PMID: 27569286
unlike ISG15, ubiquitin and FAT10 are conjugated to a similar degree to newly translated and pre-existing proteins. PMID: 27926780
We also found that FAT10 may act its oncogenic functions through regulating HOXB9. Collectively, the results suggested that FAT10 may be a novel therapeutic target for osteosarcoma patients PMID: 27279480
High expression of FAT10 is associated with glioma. PMID: 26733179
Study demonstrates how the coordinated interplay of RIG-I, TRIM25, and FAT10 regulate the antiviral innate inflammatory response. PMID: 26996158
Data suggest that ubiquitin D (UBD) provides a negative feedback on cytokine-induced activation of the endoplasmic reticulum to nucleus signaling 1 (IRE1alpha)/c-Jun N-terminal kinase (JNK) pro-apoptotic pathway in cytokine-exposed beta cells. PMID: 27044747
FAT10 can induce malignant transformation as evidenced from the anchorage-independent growth as well as in vivo tumor-forming abilities of FAT10-overexpressing NeHepLxHT cells. PMID: 24325913
repertoire of peptides eluted from MHC class I molecules was influenced by FAT10 expression PMID: 26401002
FAT10 is the only ubiquitin-like modifier known to date which directly targets its hundreds of substrates for degradation by the proteasome. (Review) PMID: 25983082
Conjugation of the ubiquitin activating enzyme UBE1 with the ubiquitin-like modifier FAT10 targets it for proteasomal degradation PMID: 25768649
the interaction of FAT10 with MAD2 is a key mechanism underlying the promalignant property of FAT10 PMID: 25422469
Results identified a novel HCC regulatory circuit involving FAT10, beta-catenin/TCF4, and HOXB9, the dysfunction of which drives invasive and metastatic character in HCC. PMID: 25056121
STAT3 and NFkappaB synergistically act for maximum induction of FAT10 expression. PMID: 24518302
transcription downregulation of the Ufm1 and FAT10 conjugation system in liver Mallory-Denk bodies formation PMID: 24893112
functional distribution of the FAT10 targets suggests that FAT10 participates in various biological processes, such as translation, protein folding, RNA processing, and macromolecular complex assembly PMID: 23862649
FAT10 expression in pancreatic ductal adenocarcinoma (PDAC) was an independent prognostic factor of patients, which might be a potential diagnostic and therapeutic target of PDAC PMID: 24492942
These results suggest that knockdown of FAT10 by adenovirus-delivered siRNA may be a promising therapeutical strategy for treatment of hepatocellular carcinoma. PMID: 24440736
FAT10 has a central role in regulating diverse aspects of the pathogenesis of hepatocellular carcinoma. PMID: 23812429
FAT10 protects cardiac myocytes against apoptosis. PMID: 23416168
Immunohistochemistry showed that FAT10 protein was over-expressed in glioma tissues. Expression level of FAT10 increase from grade I to grade IV glioma according to the results of real-time PCR, immunohistochemistry analysis and Western blot. PMID: 22402871
p62 becomes covalently mono-FAT10ylated at several lysines, and FAT10 colocalizes with p62 in p62 bodies. PMID: 22797925
FATylation of LRRFIP2 occurs on two distinct sites, each being modified by a single FAT10 moiety. PMID: 23036196
These data reveal that VHS domain of Stam2 enters the hydrophobic pocket of K48-linked diubiquitin and binds the two ubiquitin subunits with different affinities. PMID: 21121635
This study identified eEF1A1 as a FAT10-specific binding protein, and when the expression of FAT10 was reduced by siRNA knockdown, this resulted in downregulation of eEF1A1 expression in hepatoma cells. PMID: 22569823
FAT10 modification of the HCMV-derived antigen pp65 (FAT10-pp65) enhances the presentation of the HLA-A2-restricted pp65495-509 antigenic peptide and provide evidence that FAT10- pp65 differs from Ub-modified pp65 in using the proteasome machinery. PMID: 22349260
Ten SNPs in FAT10 were identified. PMID: 22292662
Data indicate the potential role of cytokine-induced FAT10 expression in regulating Uba6 pathways. PMID: 22427669
findings show how FAT10 and NUB1L dock with the 26S proteasome to initiate proteolysis; identified the 26S proteasome subunit hRpn10/S5a as the receptor for FAT10, whereas NUB1L can bind to both Rpn10 and Rpn1/S2. PMID: 22434192
implicate FAT10 in retinal cell biology and Leber congenital amaurosis pathogenesis, and reveal a new role of AIPL1 in regulating the FAT10 pathway. PMID: 22347407
In this study a crystal structure of linear diubiquitin at a resolution of 2.2 A degrees is reported. PMID: 22281738
Degradation of FAT10 is accelerated after induction of apoptosis, suggesting that it plays a role in prosurvival pathways PMID: 22072791
FAT10 plays an important role in mediating the function of TNF-alpha during tumorigenesis by inducing cell cycle deregulation and chromosomal instability. PMID: 22025632
An extract of bark from the tropical rainforest plant Byrsonima crassifolia was screened for inhibition of diubiquitin formation by the human ubiquitin-conjugating enzyme E2-25K. PMID: 22164771
Data indicate that the 20,000-bp region is telomeric of the UBD gene and contains LOC729653, a hypothetical gene. PMID: 21631897
new role for FAT10 in the pathogenesis of polyglutamine diseases. PMID: 21757738
The p53 transcriptional activity was found to be substantially enhanced in FAT10-overexpressing cells. PMID: 21396347
USE1 is not only the first E2 enzyme but also the first known substrate of FAT10 conjugation, as it was efficiently auto-FAT10ylated in cis but not in trans. PMID: 20975683
Genetic polymorphism in UBD is associated with colorectal cancer. PMID: 21351261
Reverse transcriptase-polymerase chain reaction analysis of intestinal biopsy sample pairs (at diagnosis vs treated) from 30 celiac disease patients confirmed overexpression of UBD in active disease tissue. PMID: 19808075
FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein. PMID: 12730673
FAT10 is degraded by the proteasome in ubiqitin-independent manner. PMID: 15831455
high levels of FAT10 protein in cells lead to increased mitotic nondisjunction and chromosome instability, which is mediated by an abbreviated mitotic phase and reduction in the kinetochore localization of MAD2 during prometaphase PMID: 16495226
Immunohistochemical studies demonstrated increased FAT10 expression in HIV-associated nephropathy and in autosomal dominant polycystic kidney disease. PMID: 16495380

Hide All

Subcellular Location

Nucleus. Cytoplasm. Note=Accumulates in aggresomes under proteasome inhibition conditions.

Tissue Specificity

Constitutively expressed in mature dendritic cells and B-cells. Mostly expressed in the reticuloendothelial system (e.g. thymus, spleen), the gastrointestinal system, kidney, lung and prostate gland.

Database Links

HGNC: 18795

OMIM: 606050

KEGG: hsa:10537

STRING: 9606.ENSP00000366249

UniGene: Hs.44532

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA967988A0HU
Size	US$210
	Order now
Image	Overlay Peak curve showing 786-O cells stained with CSB-RA967988A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10, 000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

UBD Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background